“Global Cholera Vaccines Market is anticipated to reach $166.36mn by 2029”, says Visiongain report

04 September 2019
Pharma

Visiongain has launched a new pharma report Cholera Vaccines Market Report 2019-2029: By Product (Dukoral, Shanchol, Vaxchora, Euvichol & Euvichol-Plus, Others), by End User (Hospitals & Clinics, Research & Academic Laboratories, Others) and by Region.

Global Cholera Vaccines Market is anticipated to grow on account of rising initiatives and awareness regarding immunization, increasing incidences of cholera, development of novel approaches for new cholera vaccine among other prominent factors. The global cholera vaccines market is anticipated to grow at a lucrative CAGR of 8.1% and anticipated to reach USD 166.36 Million by 2029.

Cholera represents an endemic condition in several poor nations across the globe. Annually, 2.8 million cases and 91,500 deaths occur in cholera endemic countries. Cholera also introduces a important financial burden beyond immediate health issues. In relation to bad sanitation and inappropriate clean water supply, inadequate health literacy and community mobilization, lack of national plans and cross-border partnerships are significant factors that impede cholera control in endemic nations. Another barrier is poor understanding of the true cholera burden owing to significant under-reporting.

With one-third of countries at danger of cholera, massive, quickly spreading and extended cholera outbreaks such as those encountered lately in Yemen and Haiti are expected to occur. Preventing such outbreaks of cholera involves providing drinking water, sanitation, and hygiene (WASH). Manufacturers have now boosted the supply of cholera vaccines, and vaccine doses have been accessible through a worldwide stockpile for emergency and endemic control since 2013. Advances in the control of packaging and vaccine temperature, reduced vaccine costs, and a targeted approach to high incidence endemic areas further enhance the usefulness of these vaccines to reduce overall cholera burden.

Asia Pacific holds majority of market share followed by Europe whereas North America is anticipated to exhibit highest growth rate over the forecast period owing to launch of first ever oral cholera vaccine i.e. Vaxchora in the year 2016.  Asia Pacific remains the largest market in terms of revenue generation owing to contributing factors such as high prevalence of disease in developing regions, high rate of immunization and growing awareness among the general public.

Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products in order to strengthen their position in the global single-cell genomics market. Companies are also expanding their R&D, distribution, and management facilities in order to expand their business and to hold a competitive edge in the market.

The comprehensive market report features companies such as Astellas Pharma Inc., AstraZeneca, Celldex Therapeutics, Inc., Emergent BioSolutions Inc., Eubiologics Co., Ltd., GlaxoSmithKline plc (GSK), Johnson & Johnson (Crucell), Merck & Co. Inc., Mitsubishi Tanabe, Pharma Corporation, PaxVax Inc., Pfizer Inc., Shantha Biotechnics Private Limited, Takeda Pharmaceutical Co. Ltd, and Valneva SE among other prominent players.

Also the research study offers market estimation and forecast for the period ranging 2019–2029 for global markets such as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Benelux, Russia, Poland, India, Japan, China, Australia, ASEAN, GCC, South Africa and North Africa.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Human Microbiome Therapeutics market set to grow to $1.6bn” by 2025 says new Visiongain report

The market for microbiome therapeutics is expected to commence around mid-2020 with the launch of new products relating to dermatology and gastrointestinal disorders.

04 December 2019

Read

“Global Next-Generation Biologics market set to grow to $42bn by 2024” says new Visiongain report

Technological developments in the next-generation biologics market will be the result of clinical development of multiple platforms in the next-generation antibody, antibody fragment and ALP sectors.

04 December 2019

Read

“Global Liquid Biopsy market set to grow to $4.9bn by 2024” says new Visiongain report

The main drivers for the growth include technological advancements such as development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

04 December 2019

Read

“Global nucleic acid isolation and purification market is anticipated to reach USD 8.16 Billion by 2030”, says Visiongain

Nucleic acid separation and purification is one of modern science and technology’s most complex and critical accomplishments.

29 November 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever